NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00122317,Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH),https://clinicaltrials.gov/study/NCT00122317,,COMPLETED,The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.,YES,"Paroxysmal Hemoglobinuria, Nocturnal",DRUG: eculizumab,"Incidence of Treatment-emergent Adverse Events, From time of consent to a maximum of 2.5 years of study treatment","Hemolysis as Measured by Change From Baseline in LDH Area Under the Curve, From time of first infusion through 24 months of study treatment|Quality of Life as Measured by FACIT-Fatigue Scale Change From Baseline, The FACIT-Fatigue scale is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life., From time of first infusion through 24 months of study treatment|Incidence of Thrombosis After Eculizumab Infusion, Thrombosis was defined as occurrence of major adverse vascular events, From time of first ever dose through last dose (up to 24 months of study treatment)",,"Alexion Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,187,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,E05-001,2005-05,2008-09,2008-10,2005-07-22,2017-06-05,2018-03-13,"Stanford University Medical Center, Division of Hematology, Stanford, California, 94305, United States|Hartford Hospital, Cancer Clinical Research Office, Hartford, Connecticut, 06102, United States|Cleveland Clinic Florida, Department of Clinical Research, Weston, Florida, 33331, United States|Indianapolis University Cancer Center, Indianapolis, Indiana, 46202, United States|Johns Hopkins University Medical Center, Baltimore, Maryland, 21205, United States|National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, 20892, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Mayo Clinic, Divison of Hematology, Rochester, Minnesota, 55902, United States|Washington University, Department of Internal Medicine/Division of Hematology, Saint Louis, Missouri, 63110, United States|NYU Clinical Cancer Center, New York, New York, 10016, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10017, United States|Duke University Medical Center, Division Cell Therapy, Heme Malignancies Program, Durham, North Carolina, 27710, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thombosis Program, Philadelphia, Pennsylvania, 19104, United States|Royal North Shore Hospital, Haematology Department, Saint Leonards, New South Wales, 2065, Australia|Princess Alexandra Hospital, Oncology Haematology Radiation Department, Woolloongabba, Queensland, 4102, Australia|The Queen Elizabeth Hospital, Haematology/Oncology Department, Woodville South, South Australia, 5011, Australia|The Royal Perth Hospital, Department of Haematology/Level 2, Perth, Western Australia, 6000, Australia|Royal Melbourne Hospital, Department of Clinical Haematology & Medical Oncology, Parkville, 3050, Australia|Ucl St. Luc, Hematology Department, Brussels, 1200, Belgium|University of Alberta, Cross Cancer Institute, Edmonton, Alberta, T6G 2B7, Canada|London Regional Cancer Centre, Clinical Research Unit Room C3080, London, Ontario, N6A4L6, Canada|Hopital Saint Louis, Centre d'investigation Clinique, Paris, Cedex, 10 75475, France|Universitatsklinikum Essen, Zentrum fur Innere Medizin, Essen, D-45147, Germany|Medizinische Hochschule Hannover, Abt. Hamatologie/Onkologie, Zentrum fur Innere Medizin, Hannover, D-30625, Germany|Universitatskliniken des Saarlandes, Innere Medizin 1, Homburg/Saar, D-66421, Germany|Institut fur Klinische Transfusionmedizin und Immunogenetik, Abtlg. Transfusionmedizin des Univ. Ulm, Ulm, D-89081, Germany|St. James's Hospital, Cancer Clinical Trial Office, Dublin, 8, Ireland|Azienda Ospedaliera Universitaria Careggi, Dipartimento di area critica medico-chirurgica, Firenze, 50139, Italy|Ospedale San Martino, Department of Hematology, Genova, I-16132, Italy|Ospedale Maggiore di Milano, Divisione di Ematologia, Milano, 35-20122, Italy|Universita degli Studi di Napoli, Divisione di Ematologia, Azienda Universitar Policlinico, Napoli, 5-80131, Italy|Ospedale San Bortolo, Divisione di Ematologia, Vicenza, 37-36100, Italy|UMC St. Radboud, Department of Hematology, Nijmegen, GA, 6525, Netherlands|Hospital Clinic i Provincial, Servicio de Hematologia, Barcelona, 08036, Spain|Hospital Universitario Germans Trias I Pujol, Servicio de Hematologia, Barcelona, 08916, Spain|Hospital De La Paz, Servicio de Hematologia, Madrid, 28046, Spain|Stockholm South Hospital, Division of Hematology, Stockholm, 118-83, Sweden|Leeds General Infirmary, D Floor Brotherton Wing, Leeds, LS1 3EX, United Kingdom|St. George's Hospital, Department of Haematology, London, SW17OQT, United Kingdom",
